Gloria Pryhuber

Dr. Gloria Pryhuber

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
YZYing Zhu
Ying Zhu
GCGeremy C. Clair
Geremy C. Clair
WCWill Chrisler
Will Chrisler
YSYufeng Shen
Yufeng Shen
RZRui Zhao
Rui Zhao
RKRyan T. Kelly
Ryan T. Kelly

29 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MGMinzhe Guo
Minzhe Guo
MMMichael P. Morley
Michael P. Morley
CJCheng Jiang
Cheng Jiang
YWYixin Wu
Yixin Wu
GLGuangyuan Li
Guangyuan Li
YXYan Xu
Yan Xu
Accurate cell type identification is a key and rate-limiting step in single-cell data analysis. Single-cell references with comprehensive cell types, reproducible and functionally validated cell identities, and common nomenclatures are much needed by the research community for automated cell type annotation, data integration, and data sharing. Here, we develop a computational pipeline utilizing the LungMAP CellCards as a dictionary to consolidate single-cell transcriptomic datasets of 104 human lungs and 17 mouse lung samples to construct LungMAP single-cell reference (CellRef) for both normal human and mouse lungs. CellRefs define 48 human and 40 mouse lung cell types catalogued from diverse anatomic locations and developmental time points. We demonstrate the accuracy and stability of LungMAP CellRefs and their utility for automated cell type annotation of both normal and diseased lungs using multiple independent methods and testing data. We develop user-friendly web interfaces for easy access and maximal utilization of the LungMAP CellRefs.

26 August 2021 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
DHDharmesh Hirani
Dharmesh Hirani
CACristina M. Alvira
Cristina M. Alvira
SDSoula Danopoulos
Soula Danopoulos
CMCarlos Milla
Carlos Milla
MDMichele Donato
Michele Donato
MAMiguel A. Alejandre Alcazar
Miguel A. Alejandre Alcazar
Rationale: Premature infants exposed to oxygen are at risk for bronchopulmonary dysplasia (BPD), which is characterised by lung growth arrest. Inflammation is important, but the mechanisms remain elusive. Here, we investigated inflammatory pathways and therapeutic targets in severe clinical and experimental BPD.Methods and results: First, transcriptomic analysis within silicocellular deconvolution identified a lung-intrinsic M1-like-driven cytokine pattern in newborn mice after hyperoxia. These findings were confirmed by gene expression of macrophage-regulating chemokines (Ccl2,Ccl7,Cxcl5) and markers (Il6,Il17A,Mmp12). Secondly, hyperoxia-activated interleukin 6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signalling was measuredin vivoand related to loss of alveolar epithelial type II cells (ATII) as well as increased mesenchymal marker.Il6null mice exhibited preserved ATII survival, reduced myofibroblasts and improved elastic fibre assembly, thus enabling lung growth and protecting lung function. Pharmacological inhibition of global IL-6 signalling and IL-6 trans-signalling promoted alveolarisation and ATII survival after hyperoxia. Third, hyperoxia triggered M1-like polarisation, possiblyviaKrüppel-like factor 4; hyperoxia-conditioned medium of macrophages and IL-6-impaired ATII proliferation. Finally, clinical data demonstrated elevated macrophage-related plasma cytokines as potential biomarkers that identify infants receiving oxygen at increased risk of developing BPD. Moreover, macrophage-derivedIL6and active STAT3 were related to loss of epithelial cells in BPD lungs.Conclusion: We present a novel IL-6-mediated mechanism by which hyperoxia activates macrophages in immature lungs, impairs ATII homeostasis and disrupts elastic fibre formation, thereby inhibiting lung growth. The data provide evidence that IL-6 trans-signalling could offer an innovative pharmacological target to enable lung growth in severe neonatal chronic lung disease.

7 April 2022 in Cell Stem Cell
Verified
Journal Article
Closed access
XXXinxiu Xu
Xinxiu Xu
KJKang Jin
Kang Jin
ABAbha S. Bais
Abha S. Bais
WZwenjuan zhu
wenjuan zhu
HYHisato Yagi
Hisato Yagi
CLCecilia Lo
Cecilia Lo

10 April 2015 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
TIThe Prematurity and Respiratory Outcomes Program Investigators
The Prematurity and Respiratory Outcomes Program Investigators
GPGloria Pryhuber
Gloria Pryhuber
NMNathalie Maitre
Nathalie Maitre
RBRoberta A Ballard
Roberta A Ballard
DCDenise Cifelli
Denise Cifelli
AHAaron Hamvas
Aaron Hamvas
With improved survival rates, short- and long-term respiratory complications of premature birth are increasing, adding significantly to financial and health burdens in the United States. In response, in May 2010, the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI) funded a 5-year $18.5 million research initiative to ultimately improve strategies for managing the respiratory complications of preterm and low birth weight infants. Using a collaborative, multi-disciplinary structure, the resulting Prematurity and Respiratory Outcomes Program (PROP) seeks to understand factors that correlate with future risk for respiratory morbidity. The PROP is an observational prospective cohort study performed by a consortium of six clinical centers (incorporating tertiary neonatal intensive care units [NICU] at 13 sites) and a data-coordinating center working in collaboration with the NHLBI. Each clinical center contributes subjects to the study, enrolling infants with gestational ages 23 0/7 to 28 6/7 weeks with an anticipated target of 750 survivors at 36 weeks post-menstrual age. In addition, each center brings specific areas of scientific focus to the Program. The primary study hypothesis is that in survivors of extreme prematurity specific biologic, physiologic and clinical data predicts respiratory morbidity between discharge and 1 year corrected age. Analytic statistical methodology includes model-based and non-model-based analyses, descriptive analyses and generalized linear mixed models. PROP incorporates aspects of NICU care to develop objective biomarkers and outcome measures of respiratory morbidity in the <29 week gestation population beyond just the NICU hospitalization, thereby leading to novel understanding of the nature and natural history of neonatal lung disease and of potential mechanistic and therapeutic targets in at-risk subjects. Clinical Trials.gov NCT01435187 .

1 February 2024 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
NGNathan Gaddis
Nathan Gaddis
JFJoshua Fortriede
Joshua Fortriede
MGMinzhe Guo
Minzhe Guo
EBEric E Bardes
Eric E Bardes
MKMichal Kouril
Michal Kouril
NSNathan Salomonis
Nathan Salomonis
An improved understanding of the human lung necessitates advanced systems models informed by an ever-increasing repertoire of molecular omics, cellular imaging, and pathological datasets. To centralize and standardize information across broad lung research efforts, we expanded the LungMAP.net website into a new gateway portal. This portal connects a broad spectrum of research networks, bulk and single-cell multiomics data, and a diverse collection of image data that span mammalian lung development and disease. The data are standardized across species and technologies using harmonized data and metadata models that leverage recent advances, including those from the Human Cell Atlas, diverse ontologies, and the LungMAP CellCards initiative. To cultivate future discoveries, we have aggregated a diverse collection of single-cell atlases for multiple species (human, rhesus, and mouse) to enable consistent queries across technologies, cohorts, age, disease, and drug treatment. These atlases are provided as independent and integrated queryable datasets, with an emphasis on dynamic visualization, figure generation, reanalysis, cell-type curation, and automated reference-based classification of user-provided single-cell genomics datasets (Azimuth). As this resource grows, we intend to increase the breadth of available interactive interfaces, supported data types, data portals and datasets from LungMAP, and external research efforts.